Actively Recruiting
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Led by Nagoya City University · Updated on 2025-11-20
100
Participants Needed
1
Research Sites
830 weeks
Total Duration
On this page
Sponsors
N
Nagoya City University
Lead Sponsor
J
Japan Clinical Oncology Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
CONDITIONS
Official Title
Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed invasive breast carcinoma
- Stage II or III breast cancer
- ECOG performance status of 0 or 1
- Age between 18 and 80 years
You will not qualify if you...
- Continuous use of steroid drugs or other immunosuppressants
- History or presence of interstitial lung disease or pulmonary fibrosis
- Infection requiring systemic treatment
- Active second cancer, except for completely resected basal cell carcinoma, squamous cell carcinoma at clinical stage I, carcinoma in situ, mucosal carcinoma, superficial bladder carcinoma, gastrointestinal cancer curatively resected by ESD or EMR, or other cancers without recurrence for more than 5 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nagoya City University
Nagoya, Aichi-ken, Japan, 467-8601
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here